Premium
Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas
Author(s) -
Iwadati Yasuo,
Fujimoto Shuichi,
Tagawa Masatoshi,
Namba Hiroki,
Sueyoshi Kanji,
Hirose Masayoshi,
Sakiyama Shigeru
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960621)69:3<236::aid-ijc14>3.0.co;2-5
Subject(s) - glioma , cancer research , carcinogenesis , anaplastic astrocytoma , mutation , tumor suppressor gene , radiosensitivity , malignancy , gene , chemotherapy , biology , cancer , gene mutation , radiation therapy , pathology , medicine , astrocytoma , genetics
Loss of p53 function is involved in tumorigenesis of various human cancers, but the relation between mutation of the p53 tumor‐suppressor gene and the chemo‐ and radiosensitivity of tumors remains unclear. Mutated p53 gene in malignant glioma is often associated with progression and recurrence of malignancy, and these events are closely linked with increased resistance to both chemotherapy and radiation. We have examined the status of the p53 gene in malignant gliomas obtained from 34 patients (glioblastoma: 29 cases, anaplastic astrocytomas: 5 cases). The chemosensitivities of these specimens using 28 kinds of anti‐cancer agents were determined using an in vitro assay system. Overall, 12 mutated cases of p53 gene were found in malignant glioma samples. The mean numbers of effective agents were 0.58 for the tumor samples with p53 mutations and 5.00 for tumors without mutations. Our data indicate that p53 gene mutation predisposes to decreased cell killing via chemotherapy in malignant gliomas. © 1996 Wiley‐Liss, Inc.